Regulatory

Part:BBa_K4829004:Design

Designed by: Modernatx   Group: iGEM23_IISc-Bengaluru   (2023-10-04)


5' UTR patented by Modernatx


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

This is NOT of our design. However, what follows is a brief summary of the design present.

  • The elements on both the 5′- and 3′-ends of the coding sequence play a role in determining the stability and translation of mRNA. By adjusting the 5′-UTR of mRNA, which has secondary structures that certain cellular RNA binding proteins can identify, the efficiency of mRNA translation can be maximized. This is particularly important for mRNAs that have applications in therapeutics and vaccines. Commonly, the α-globin or β-globin UTRs from either Xenopus laevis or humans have been utilized in the design of mRNA vaccines because of their robust stability.
  • A GC-rich tract CCCCGGCGCC was included, just upstream of the Kozak consensus sequence.
  • Kozak sequence: GCCACCAUG


Source

It was derived from Beta globin UTRs of humans.

References

Javier T. Granados-Riveron, Guillermo Aquino-Jarquin, Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2,Biomedicine & Pharmacotherapy,Volume 142,2021,111953,ISSN 0753-3322,https://doi.org/10.1016/j.biopha.2021.111953.